An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

"We found that pharmacologically targeting a single kinase, CDK2, can trigger two distinct cellular responses depending on ...

Cyclin-dependent kinases 4 and 6 (CDK4/6) are crucial cell cycle regulators and have become significant targets in breast cancer therapy. Current CDK4/6 inhibitors, while effective, often come with ...

Future studies could explore the development of more selective inhibitors and their combinatory effects with existing treatments. An interesting new therapeutic approaches, acting on the induction of ...

This process is triggered by various stimuli, including oxidative stress, chromatin modifications and oncogene activation, characterized by irreversible cell-cycle arrest, resistance to apoptosis and ...